HB 62

  • Delaware House Bill
  • 151st General Assembly (2021-2022)
  • Introduced in House Jan 07, 2021
  • House
  • Senate
  • Governor

An Act To Amend Title 6 Of The Delaware Code Relating To The Prohibition Of Excessive And Unconscionable Prices For Prescription Drugs.

Abstract

This Act is based on a Model Act to Prevent Excessive and Unconscionable Prices for Prescription Drugs developed by the National Academy for State Health Policy. It prohibits manufacturers from raising the price of prescription drugs outside of certain market conditions that might justify a price hike. It is specifically limited to the prices charged to consumers in the State of Delaware for generic and off-patent drugs. It authorizes the Attorney General to investigate price increases identified by State agencies above a certain threshold. Manufacturers or distributors may be fined up to $10,000 per day for sales which violate the Act. Each sale of a drug excessively and unconscionably priced constitutes a separate violation. A manufacturer or distributor is prohibited from withdrawing a generic or off-patent drug for sale in this State to avoid application of the Act.

Bill Sponsors (20)

Votes


No votes to display

Actions


Jan 07, 2021

House

Introduced and Assigned to Economic Development/Banking/Insurance & Commerce Committee in House

  • Introduction
  • Referral-Committee
Economic Development/Banking/Insurance & Commerce

Bill Text

Bill Text Versions Format
Bill Text PDF HTML

Related Documents

Document Format
No related documents.

Sources

Data on Open States is updated periodically throughout the day from the official website of the Delaware General Assembly.

If you notice any inconsistencies with these official sources, feel free to file an issue.